Showing 12,141 - 12,160 results of 99,146 for search '(( 5 ((((ng decrease) OR (a decrease))) OR (nn decrease)) ) OR ( 50 ms decrease ))', query time: 1.38s Refine Results
  1. 12141
  2. 12142
  3. 12143
  4. 12144

    Silencing GRK2 and GRK3 attenuate C3aR desensitization but GRK5 and GRK6 do not. by Qiang Guo (218747)

    Published 2013
    “…<p>(A) shRNA control, (B) GRK2, (C) GRK3, (D) GRK5 and (E) GRK6 KD cells were loaded with Indo-1 (1 µM), stimulated with C3a (100 nM) for 5 min and intracellular Ca<sup>2+</sup> mobilization was determined (black solid lines). …”
  5. 12145
  6. 12146
  7. 12147
  8. 12148

    Young aphasia case study: Source localisation results of the context effect (constrained vs unconstrained naming) in A. and control by Vitoria Piai (9547418)

    Published 2022
    “…Power was thresholded at ±1.5. Corresponding Cohen’s d maps (bottom two rows) for control (third row) and A. …”
  9. 12149
  10. 12150
  11. 12151
  12. 12152
  13. 12153
  14. 12154
  15. 12155
  16. 12156

    Mendelian randomization results with COVID-19. by Alish B. Palmos (5857379)

    Published 2022
    “…The bottom section shows results consistent with five blood markers being significantly causally associated with an increased risk for the need of respiratory support/death due to COVID-19 and eight blood markers causally associated with a decreased risk for the need of respiratory support/death due to COVID-19, as well as one protein decreasing risk for the need of respiratory support/death due to COVID-19. …”
  17. 12157
  18. 12158

    Data_Sheet_1_A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.PDF by Sofia Sandgren (17017017)

    Published 2023
    “…/mL (IQR 285.4) (p = 0.05); serum month 24: 6.7 pg/mL (IQR 4.7) (p < 0.01); serum month 60: 7.2 pg/mL (IQR 4.7) (p < 0.01)], compared to baseline [CSF: 1014 pg/mL (IQR 2832.5); serum 8.6 pg/mL (IQR 17.4)].</p>Conclusion<p>In this real-world mono-center population, we observed a progression-free survival of 69%, cumulative NEDA-3 of 33%, and reduced NfL levels, over a five-year follow-up. …”
  19. 12159
  20. 12160